信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

交易中 08-20 10:08:21

104.400

+6.150

+6.26%

最高105.100	最低100.800	成交量898.27万
今开102.400	昨收98.250	日振幅4.38%
总市值1,821亿	流通市值1,821亿	总股本17.44亿
成交额9.24亿	换手率0.52%	流通股本17.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":104.4,"timestamp":1787191698294,"preClose":98.25,"halted":0,"volume":8982727,"delay":0,"changeRate":0.0625954198473283,"floatShares":1744000000,"shares":1744000000,"eps":0.5482873216613208,"marketStatus":"交易中","change":6.15,"latestTime":"08-20 10:08:21","open":102.4,"high":105.1,"low":100.8,"amount":923934178,"amplitude":0.043766,"askPrice":104.4,"askSize":5000,"bidPrice":104.3,"bidSize":14500,"shortable":3,"etf":0,"ttmEps":0.5482873216613208,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1787198400000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":98.25,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":6.90867,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.53,"impliedVolPercentile":0.6327},"requestUrl":"/m/hq/s/01801/tweets","defaultTab":"tweets","newsList":[{"id":"1196274020","title":"异动解读｜信达生物盘中上涨4.43%，大摩上调目标价至138.5港元叠加中报高预期催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1196274020","media":"行情直击","labels":["dataReport"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196274020?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:32","pubTimestamp":1787189547,"startTime":"0","endTime":"0","summary":"8月20日，信达生物盘中上涨4.43%，报101.2港元，成交额1.95亿港元。消息面上，摩根士丹利于8月19日发布研报，基于公司上半年产品收入强劲表现，上调目标价至138.5港元。此前贝莱德于8月12日增持公司13.95万股，每股作价95.375港元，增持后持股比例升至5.01%。公司已公告将于8月25日召开董事会审议中期业绩，上半年产品收入超82亿元人民币，同比增长逾55%，其中第二季度收入超43亿元，同比增长约60%，远超市场预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物盘中上涨4.43%，大摩上调目标价至138.5港元叠加中报高预期催化","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443427","title":"大摩：信达生物(01801.HK)上半年产品收入强劲 上调目标价至138.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443427","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660443427?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:25","pubTimestamp":1787124318,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2097828631.EUR","KURE","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","LU0502904849.HKD","LU2488822045.USD","BK1161","LU0455707207.USD","LU1188198961.HKD","BK1589","LU1969619763.USD","LU2097828714.EUR","HK0000165453.HKD","01801","LU0463099449.HKD","LU2328871848.SGD","LU0326950275.SGD","BK1583","LU2097828474.EUR","LU0244354667.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182910826","title":"异动解读｜信达生物盘中上涨3.47%，贝莱德增持叠加中报高预期催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1182910826","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182910826?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:48","pubTimestamp":1787104089,"startTime":"0","endTime":"0","summary":"8月19日，信达生物盘中上涨3.47%，报100.1港元，成交额5.89亿港元。消息面上，贝莱德于8月12日增持公司13.95万股，每股作价95.375港元，增持后持股比例升至5.01%。同时，公司将于8月25日召开董事会审议中期业绩，此前已披露上半年产品收入超82亿元人民币，同比增长逾55%，其中第二季度收入超43亿元，同比增长约60%，远超市场预期。此外，公司近期联合美团买药探索即时零售模式，拓展商业化渠道，进一步强化增长预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物盘中上涨3.47%，贝莱德增持叠加中报高预期催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660648441","title":"贝莱德增持信达生物(01801)13.95万股 每股作价95.375港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660648441","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660648441?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:14","pubTimestamp":1786965266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月12日，贝莱德增持信达生物(01801)13.95万股，每股作价95.375港元，总金额约为1330.48万港元。增持后最新持股数目约为8731.79万股，最新持股比例为5.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BDGV0183.EUR","BK4135","01801","LU2488822045.USD","LU2097828474.EUR","LU2242644610.SGD","LU1481011911.USD","BLK","KURE","LU2430703095.HKD","LU0070302665.USD","LU1988902786.USD","LU0772969993.USD","LU1074936037.SGD","LU1280957306.USD","BK1161","BK1589","BK1583","IE00BGHQF748.EUR","IE00BVYPNW00.USD","LU2097828557.USD","IE00BVYPNV92.GBP","BK4535","LU1670627923.USD","LU1599440770.SGD","LU0648001328.SGD","LU2097828805.USD","EWH","LU0208291251.USD","LU1064131342.USD","LU2430703178.SGD","FDFF","LU1969619763.USD","LU2592432038.USD","LU0455707207.USD","LU0326950275.SGD","LU0731783394.SGD","LU0731783048.USD","BK4567","BK4581","IE00B3PB1722.GBP","BK4534","IE00BGHQF631.EUR","LU0130102774.USD","LU1201861249.SGD","BK4585","LU1291159041.SGD","LU2328871848.SGD","LU2430703251.USD","LU1481011671.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173380078","title":"港股创新药概念股盘中走强，和黄医药涨超7%，药明生物、金斯瑞生物科技涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173380078","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173380078?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:08","pubTimestamp":1786932515,"startTime":"0","endTime":"0","summary":"8月17日，港股创新药概念股盘中走强，$和黄医药(00013)$涨超7%，$药明生物(02269)$、$海西新药(02637)$、$金斯瑞生物科技(01548)$涨超5%，$药明康德(02359)$、$药明合联(02268)$涨超4%，$信达生物(01801)$、$石药集团(01093)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","HK0000320223.HKD","LU0708995583.HKD","LU0469268626.HKD","LU0244354667.USD","LU1242518931.SGD","LU0819121731.USD","LU1152091754.HKD","LU0359202008.SGD","KURE","LU0359201612.USD","LU0823426308.USD","LU0856984785.SGD","LU1242518857.USD","LU1951186391.HKD","HCM","LU0072913022.USD","LU1813983027.USD","LU1993786604.SGD","00013","BK1191","02637","159992","LU2488822045.USD","LU0588546209.SGD","KCAI","LU0314109678.HKD","LU1969619763.USD","BK1589","LU0348766576.USD","02269","IE00B5MMRT66.SGD","LU2045819591.USD","LU1720050803.USD","MEDX","BK1610","01801","LU0326950275.SGD","LU1188198961.HKD","LU0051755006.USD","LU0572944931.SGD","LU0348735423.USD","LU1226287875.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU2097828474.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","LU1226287792.SGD","LU3063872942.SGD","BK1515","LU0128526141.USD","LU0456827905.SGD","LU0307460666.USD","LU2242644610.SGD","LU0043850808.USD","BK1141","LU0417516902.SGD","LU0029874061.USD","BK4585","BK1587","LU2125910500.SGD","BK1161","LU1880383366.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0823426480.USD","LU0502904849.HKD","LU2097828805.USD","SG9999002463.SGD","LU0417516738.SGD","LU1008478684.HKD","LU1152091168.USD","LU0456846285.SGD","VXUS","SG9999004220.SGD","02359","LU0979878070.USD","LU1960683339.HKD","BK4007","LU0039217434.USD","LU0315179316.USD","LU0516422952.EUR","SG9999014674.SGD","01548","LU0320764599.SGD","SG9999002562.SGD","LU1226288253.USD","LU2097828557.USD","LU0181495838.USD","LU2328871848.SGD","BK4531","HK0000306685.HKD","LU1328277881.USD","BK4588","LU0067412154.USD","LU0455707207.USD","LU1046422090.SGD","LU0348825331.USD","IBBQ","HK0000306701.USD","LU0348767384.USD","LU0516423091.SGD","BK1583","HK0000320264.USD","LU0501845795.SGD","LU0516422366.SGD","LU0880133367.SGD","BK1588","06978","LU0516422440.USD","IE00BZ08YT58.USD","LU1807302812.USD","LNGR","LU0516423174.USD","LU2097828714.EUR","02268","LU1794554557.SGD","LU0463099449.HKD","LU1226288170.HKD","LU2039709279.SGD","LU2097828631.EUR","LU1226287529.USD","01093","LU1688375341.USD","BK1574","LU0052750758.USD","IE0008368742.USD","BK1576","IE00B543WZ88.USD","BK1521","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188749416","title":"异动解读｜信达生物盘中上涨3.78%，上半年业绩强劲叠加即时零售新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1188749416","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188749416?lang=zh_cn&edition=full","pubTime":"2026-08-17 10:07","pubTimestamp":1786932439,"startTime":"0","endTime":"0","summary":"8月17日，信达生物盘中上涨3.78%，报97.35港元，成交额2.15亿港元。消息面上，公司近日联合美团买药探索即时零售模式并首发小规格新品，拓展商业化渠道。同时，公司已公告将于8月25日召开董事会审议中期业绩，市场对即将发布的中报抱有较高期待。此前公司披露上半年产品收入超82亿元人民币，同比增长55%以上，其中第二季度产品收入超43亿元，同比增长约60%，远超市场预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物盘中上涨3.78%，上半年业绩强劲叠加即时零售新布局","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659118971","title":"信达生物联合美团买药探索即时零售 首发小规格新品","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659118971?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:54","pubTimestamp":1786686872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KURE","LU0244354667.USD","BK1161","BK4209","LU1188198961.HKD","LU0455707207.USD","LU0463099449.HKD","LU1969619763.USD","LU0326950275.SGD","DRAG","LU0502904849.HKD","LU2097828805.USD","LU2097828714.EUR","LU2097828557.USD","03690","LU2488822045.USD","BK1583","MPNGY","BK1589","01801","HK0000165453.HKD","LU2097828631.EUR","LU2097828474.EUR","BK4122","LU2328871848.SGD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140399042","title":"信达生物(01801)公告将于2026年8月25日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1140399042","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140399042?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:06","pubTimestamp":1786352817,"startTime":"0","endTime":"0","summary":"信达生物(01801)8月10日在香港发布公告称，公司董事会已排定于2026年8月25日（星期二）召开会议，主要议程包括考虑并批准集团截至2026年6月30日止六个月的中期业绩及相关发布事宜。\n董事会目前成员构成为：主席兼执行董事俞德超博士；执行董事奚浩先生、张倩女士；以及独立非执行董事Charles Leland Cooney博士、許懿尹女士、Gary Zieziula先生、陳樹云先生和Stephen A. Sherwin博士。\n公司表示，将在董事会审议通过后对外公布2026年中期业绩。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658867999","title":"玛仕度肽降价求生，信达生物的高估值能撑多久","url":"https://stock-news.laohu8.com/highlight/detail?id=2658867999","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658867999?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:51","pubTimestamp":1786348260,"startTime":"0","endTime":"0","summary":"8月5日，信达生物发布2026年上半年及第二季度收入公告。营收高速增长，股价顺势走高，公告发布当日，信达生物股价收涨4.15%，市盈率高达174倍，超高估值充分体现了市场对其未来增长的强烈期待。同时，玛仕度肽存在明显的上市时间劣势。信达生物选择顶风作案，本质上是国内GLP-1赛道内卷白热化的缩影。财务数据显示，2025年信达生物研发支出为26.24亿元，研发费用率仅20.1%，较2024年28.4%的比例出现明显下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-08-10/doc-inimvnpm8113256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","LU2488822045.USD","BK1583","LU1188198961.HKD","HK0000165453.HKD","LU2097828631.EUR","LU2097828557.USD","01801","BK1589","LU0326950275.SGD","KURE","BK1161","LU2097828805.USD","LU0463099449.HKD","LU0502904849.HKD","LU0244354667.USD","LU2328871848.SGD","LU2097828714.EUR","LU2097828474.EUR","LU2242644610.SGD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184223255","title":"异动解读｜信达生物盘中上涨3.06%，上半年业绩大超预期叠加多家大行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1184223255","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184223255?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:26","pubTimestamp":1786328800,"startTime":"0","endTime":"0","summary":"8月10日，信达生物盘中上涨3.06%，报97.75港元/股，成交额7.39亿港元。消息面上，公司近日披露上半年产品收入超82亿元人民币，同比增长55%以上，其中第二季度产品收入超43亿元人民币，同比增长约60%，远超市场此前预期的69亿元。此外，公司宣布Ibi363联合贝伐珠单抗治疗晚期结直肠癌关键注册研究完成首例患者入组，业绩兑现与研发催化共振支撑股价持续走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657697002","title":"ETF异动 | 南方恒生生科(03174)涨超5% 创新药龙头业绩集中爆发 全球产业链景气度维持高位","url":"https://stock-news.laohu8.com/highlight/detail?id=2657697002","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657697002?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:56","pubTimestamp":1786085810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，南方恒生生科涨超5%，截至发稿，涨5.4%，报3.628港元，成交额723.74万港元。百济神州上半年归母净利润达32.71亿元，同比增长627.1%，并上调全年营收预期。信达生物上半年产品收入同比增长超过55%，该公司综合产品线保持强劲增长。兴业证券表示，全球创新药及产业链景气度维持高位，多家海外MNC与CXO披露中报盈喜并上调2026年全年指引，验证全球创新药研发投入与产业链需求仍处于较高景气区间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02269","LU1046422090.SGD","MEDX","BK1161","BK1587","BK4550","LU1961090484.USD","LU0540923850.HKD","BK1500","SG9999002562.SGD","03174","LU1251922891.USD","159992","LU0348825331.USD","06978","LU0051755006.USD","LU0320764599.SGD","LU0708995583.HKD","LU0348767384.USD","LU1242518857.USD","BK1521","KURE","LU0572944931.SGD","09926","FDN","LNGR","LU0516422366.SGD","LU1719994722.HKD","IBBQ","02359","LU0823426480.USD","LU1770034418.SGD","BK1583","LU2399975544.HKD","LU0456827905.SGD","IE00B0JY6N72.USD","LU3063872942.SGD","01801","LU2097828474.EUR","LU0348827113.USD","BK4585","LU0348766576.USD","LU0502904849.HKD","LU0455707207.USD","LU1720050803.USD","LU2476274720.SGD","BK4588","LU2125910500.SGD","LU0181495838.USD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125719120","title":"异动解读｜信达生物盘中上涨3.02%，多家大行上调目标价叠加研发进展催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1125719120","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125719120?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:27","pubTimestamp":1786084036,"startTime":"0","endTime":"0","summary":"8月7日，信达生物盘中上涨3.02%，报93.7港元/股，成交额10.81亿港元。消息面上，公司近日披露上半年产品收入超82亿元人民币，同比增长55%以上，其中第二季度产品收入超43亿元人民币，同比增长约60%，远超市场预期。高盛将目标价上调至111.68港元，交银国际给予118港元目标价，花旗重申115港元目标价，均维持\"买入\"评级。此外，公司宣布Ibi363联合贝伐珠单抗治疗晚期结直肠癌关键注册研究完成首例患者入组，研发管线持续推进，基本面利好共振支撑股价走强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物盘中上涨3.02%，多家大行上调目标价叠加研发进展催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680111","title":"“创新药双雄”半年业绩同台：百济神州赚全球的钱，信达生物吃国内的饭，行业跨过“烧钱拐点”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680111","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657680111?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:54","pubTimestamp":1786013642,"startTime":"0","endTime":"0","summary":"相比老大哥百济神州，创新药二哥信达生物的增速同样亮眼，高盛发布研报称，第二季度产品胜过该行预测的41亿元人民币，反映商业化动能持续加快。创新药企业绩兑现元年：三大难题待解从创新药双雄以及荣昌生物等头部创新药企的业绩公告来看，创新药行业已经跨过盈亏平衡点，从“管线溢价”切到“业绩兑现”。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786011933147703386","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159992","BK1161","LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","BK4585","LU1303224171.USD","LU1719994722.HKD","01801","BK1589","LU2242644610.SGD","LU2488822045.USD","06978","LU0307460666.USD","BK1583","06160","LU2097828805.USD","LU0455707207.USD","MEDX","ONC","HK0000165453.HKD","688235","LU2097828631.EUR","LU0502904849.HKD","BK0239","BK1500","BK1588","LNGR","LU2328871848.SGD","LU0588546209.SGD","LU2097828474.EUR","BK4588","IBBQ","BK4139","LU2097828557.USD","BK4526","KURE","LU2097828714.EUR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179645804","title":"信达生物公布2026年7月股份变动月报表，股本增至约17.44亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1179645804","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179645804?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:48","pubTimestamp":1786009684,"startTime":"0","endTime":"0","summary":"2026年8月6日，信达生物制药披露2026年7月股份变动月报表。报告显示，截至2026年7月31日，公司法定或注册股本维持在50,000美元，共5,000,000,000股普通股，面值为0.00001美元，数量未发生变化。库藏股数量维持为0股，公司指出截至本月底仍符合香港联交所的最低公众持股量要求。截至2026年7月末，公司已发行普通股总数为1,743,682,629股。公司声明，本次各项发行或转让均获得董事会正式授权，并遵守香港联交所《上市规则》和相关监管规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683128","title":"高盛：信达生物(01801)上半年产品收入增长强劲 目标价升至111.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657683128?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:37","pubTimestamp":1786001837,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，信达生物上半年产品收入超过82亿元人民币，同比增长55%；第二季度产品收入超过43亿元人民币，同比增长约60%，胜过该行预测的41亿元人民币，反映商业化动能持续加快。以现金流折现率计，目标价由107.04港元上调至111.68港元，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657738501","title":"大行评级丨高盛：信达生物上半年产品收入增长强劲，目标价升至111.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657738501","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657738501?lang=zh_cn&edition=full","pubTime":"2026-08-06 13:25","pubTimestamp":1785993919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1589","LU2097828714.EUR","LU2328871848.SGD","LU2097828474.EUR","LU0455707207.USD","LU2097828805.USD","LU1969619763.USD","01801","LU2242644610.SGD","LU2488822045.USD","BK1161","HK0000165453.HKD","LU2097828557.USD","LU2097828631.EUR","KURE","LU0502904849.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570021","title":"【券商聚焦】交银国际维持信达生物（01801）买入评级 指2Q26产品收入超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570021","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657570021?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:14","pubTimestamp":1785978872,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，信达生物 1H26实现产品收入超82亿元，同比增超55%，超越该机构和市场预期；其中2Q26收入同比增约60%。公司2027年中国内地产品收入200亿元目标的兑现确定性有望进一步夯实。该机构基于1H26产品收入表现及对外合作收入的确认节奏的最新预期，调整2026-28年财务预测。该机构将DCF估值模型向前滚动一年，得到最新目标价118港元，维持买入评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987591","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150595603","title":"信达生物宣布：Ibi363/Tak-928联合贝伐珠单抗治疗晚期结直肠癌关键注册研究首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1150595603","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150595603?lang=zh_cn&edition=full","pubTime":"2026-08-06 08:01","pubTimestamp":1785974470,"startTime":"0","endTime":"0","summary":"信达生物（Innovent Bio）正式宣布，其用于治疗中国晚期结直肠癌的关键注册性研究已完成首例患者给药。这项研究评估的是Ibi363/Tak-928——一种偏向PD-1/IL-2α的双特异性融合蛋白——与贝伐珠单抗联合使用的疗效。\n该研究针对的是末线治疗的晚期结直肠癌患者，旨在验证这一创新组合疗法在临床中的安全性与有效性。作为一项关键性的注册研究，其结果或将影响未来中国结直肠癌治疗格局的变化。\n此次里程碑事件，标志着信达生物在肿瘤免疫领域，尤其是针对晚期结直肠癌的探索，迈出了至关重要的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU1969619763.USD","LU2097828714.EUR","LU2097828805.USD","LU2328871848.SGD","BK1161","BK1589","01801","LU0455707207.USD","LU2097828474.EUR","HK0000165453.HKD","LU2097828631.EUR","LU2097828557.USD","KURE","LU0502904849.HKD","BK1583","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657170515","title":"花旗：信达生物重申“买入”评级 目标价115港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657170515","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657170515?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:56","pubTimestamp":1785912960,"startTime":"0","endTime":"0","summary":"模拟交易客户端花旗发布研报称，信达生物公布2026年上半年产品收入超过82亿元人民币，同比增长55%以上，其中第二季度产品收入超过43亿元人民币，同比增长约60%，表现优于市场预期。在肿瘤领域，五款新纳入国家医保目录的酪氨酸激酶抑制剂市场渗透率持续提升。同时，公司与礼来达成唯择成功拓展至乳腺癌治疗领域。花旗认为信达生物是中国生物科技板块的首选股之一，重申“买入”评级，目标价115港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-05/doc-inimfwqr1475464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01801","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651516","title":"里昂：信达生物(01801)上半年产品收入远超预期 成股价正面催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651516","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657651516?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:45","pubTimestamp":1785912322,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，信达生物(01801)公布2026年上半年产品收入82亿元人民币，同比增长55%，远超市场预期的69亿元人民币。考虑到市场早前忧虑反贪腐措施可能拖累医药行业上半年业绩，今次产品销售表现特别令人鼓舞，相信将成为股价今日的正面催化剂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","HK0000165453.HKD","BK1583","LU2097828714.EUR","LU0502904849.HKD","KURE","BK1161","LU1969619763.USD","LU2242644610.SGD","BK1589","LU2097828557.USD","LU2488822045.USD","LU0455707207.USD","LU2328871848.SGD","01801","LU2097828631.EUR","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0622},{"period":"3month","weight":0.1902},{"period":"6month","weight":0.0826},{"period":"1year","weight":0.0051},{"period":"ytd","weight":0.2885}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.019948},{"month":8,"riseRate":0.75,"avgChangeRate":0.01684},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}